Us Bancorp \De\ Zymeworks Inc. Transaction History

Us Bancorp \De\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$4.82 - $7.7 $1,532 - $2,448	-318 Reduced 87.36%	46 $0
Q1 2022 May 11, 2022	BUY	$6.0 - $16.98 $102 - $288	17 Added 4.9%	364 $2,000
Q4 2021 Feb 11, 2022	SELL	$15.19 - $29.33 $4,951 - $9,561	-326 Reduced 48.44%	347 $5,000
Q2 2021 Aug 05, 2021	SELL	$26.5 - $38.23 $153,488 - $221,428	-5,792 Reduced 89.59%	673 $23,000
Q1 2021 Apr 28, 2021	SELL	$29.83 - $56.81 $9,485 - $18,065	-318 Reduced 4.69%	6,465 $204,000
Q4 2020 Feb 04, 2021	BUY	$39.12 - $54.99 $26,953 - $37,888	689 Added 11.31%	6,783 $321,000
Q3 2020 Nov 10, 2020	BUY	$29.21 - $46.58 $139,127 - $221,860	4,763 Added 357.85%	6,094 $284,000
Q2 2020 Aug 07, 2020	SELL	$33.67 - $40.0 $4,410 - $5,240	-131 Reduced 8.96%	1,331 $48,000
Q1 2020 May 13, 2020	SELL	$24.28 - $49.8 $37,464 - $76,841	-1,543 Reduced 51.35%	1,462 $52,000
Q3 2019 Nov 08, 2019	BUY	$22.78 - $29.08 $34,283 - $43,765	1,505 Added 100.33%	3,005 $75,000
Q3 2018 Nov 01, 2018	BUY	$12.21 - $16.61 $6,105 - $8,305	500 Added 50.0%	1,500 $24,000
Q2 2018 Aug 08, 2018	BUY	$11.13 - $21.86 $11,130 - $21,860	1,000 New	1,000 $15,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $872M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.